Prodrugs of CC-1065 analogs

Details Prodrugs of CC-1065 analogs Prodrugs of CC-1065 analogs

2006-05-23

2006-05-23

Solola, Taofiq (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S318000, C514S411000, C544S358000

Reexamination Certificate

active

07049316

ABSTRACT:
Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.

REFERENCES:
patent: 5475092 (1995-12-01), Chari et al.
patent: 5585499 (1996-12-01), Chari et al.
patent: 5846545 (1998-12-01), Chari et al.
patent: 6060608 (2000-05-01), Boger
patent: 6534660 (2003-03-01), Chari et al.
patent: 6548530 (2003-04-01), Boger
patent: 6586618 (2003-07-01), Zhao et al.
patent: 2003/0195365 (2003-10-01), Zhao et al.
Katsushige Gomi, et al., “Anticellular and Antitumor Activity of Duocarmycins, Novel Antitumor Antibiotics,” Jpn. J. Cancer Research, Jan. 1992, pp. 113-120, vol. 83.
Chong-Soon Lee, et al., “Determination of the Structural Features of (+)-CC-1065 That Are Responsible for Bending and Winding of DNA,” Chem. Res. Toxicol., 1991, pp. 203-213, vol. 4, No. 2.
David H. Swenson, et al, “Evaluation of DNA Binding Characteristics of Some CC-1065 Analogs,” Chem.-Biol. Interactions, 1988, pp. 199-213, vol. 67.
Li H. Li, et al., “Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065,” Investigational New Drugs, 1991, pp. 137-148, vol. 9, No. 2.
Bruce W. Ennis, et al., “The EGF Receptor System as a Target for Antitumor Therapy,” Cancer Investigation, 1991, pp. 553-562, vol. 9, No. 5.
Magda C. Gutowski, et al., “Epidermal Growth Factor Receptor-reactive Monoclonal Antibodies: Xenograft Antitumor Activity Alone and as Drug Immunoconjugagtes,” Cancer Res. 1991, pp. 5471-5475, vol. 51, No. 20.
Dale L. Boger, et al., “Parallel Synthesis and Evaluation of 132 (+)-1,2,9, 9aTetrahydrocyclopropa[c] benz [e] indol -4 -one(CBI Anaologues of CC-1065 and the Duocarmycins Defining the Contribution of the DNA-Binding Doman,” Journal of Organic Chemistry, 2001, 66(20), 6654-6661. (abstract).
Yuqiang Wang, “Synthesis and Preliminary Biological Evaluations of CC-1065 Analogues: Effects of Different Linkers and Terminal Amides on Biological Activity,” Journal of Medicinal Chemistry (2000), 43(8), 1541-1549.

Affiliated with

Also associated with

Rating

Prodrugs of CC-1065 analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrugs of CC-1065 analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs of CC-1065 analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3552815